Subsequent Events

12 Months Ended

Dec. 31, 2019

Subsequent Events

Subsequent Events

15.          Subsequent Events

The Company has evaluated subsequent events that may require adjustments to or disclosure in the consolidated financial statements through March 11, 2020, the date on which the consolidated financial statements were available to be issued.

In February, the Company entered into a research collaboration agreement with Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (“Merck”), to identify the antigenic targets of select antibodies discovered by Atreca with potential utility in oncology. Under the terms of the agreement, Atreca received a nominal upfront cash payment and following target identification, both companies will have freedom to advance therapeutic candidates against the targets identified under the collaboration, with development and commercial milestones payable by either party.